Protalix BioTherapeutics, Inc. (PLX) Stock Forecast
PLX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $11.00 average of analyst targets
- Upside to target
- +319.8% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.02
- 52-week range
- $1.67 – $3.15
PLX analyst ratings
1 analystsNumber of analysts at each rating.
PLX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PLX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.02 | −$0.05 | $0.01 | $0.03 | −166.7% | 2 |
| Current fiscal year (2026) | $0.24 | $0.19 | $0.29 | −$0.08 | +400.0% | 2 |
| Next fiscal year (2027) | $0.05 | −$0.01 | $0.11 | $0.24 | −79.2% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PLX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $12.4M | $11.7M | $13.1M | −30.5% | 2 |
| Current fiscal year (2026) | $82.2M | $81.6M | $82.7M | +55.8% | 2 |
| Next fiscal year (2027) | $66.5M | $60.3M | $72.7M | −19.1% | 2 |
PLX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PLX revenue: reported and forecast
PLX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.01 | −$0.01 | −$0.01 | −$0.05 | −$0.02 | +100.0% | 0 up · 0 down |
| Current fiscal year (2026) | $0.20 | $0.20 | $0.20 | $0.19 | $0.24 | +23.1% | 2 up · 0 down |
| Next fiscal year (2027) | $0.05 | $0.05 | $0.05 | $0.06 | $0.05 | 0.0% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PLX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PLX beat in 4 of 12.
What analysts expect from PLX
1 analysts cover Protalix BioTherapeutics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.00, 319.8% above the latest close of $2.62. Analysts expect earnings of $0.24 per share for 2026, +400.0% from a year earlier. For 2027 the average estimate is $0.05 per share on revenue of $66.5 million. Protalix BioTherapeutics beat the EPS estimate in 4 of the last 12 quarters.
Related: PLX income statement, PLX key metrics, PLX chart. See the PLX stock overview for the latest quote and news.
PLX forecast FAQ
What is Protalix BioTherapeutics's price target?
The average analyst price target for Protalix BioTherapeutics is $11.00, 319.8% above the latest close of $2.62.
Is Protalix BioTherapeutics a buy, hold or sell?
Of 1 analysts covering Protalix BioTherapeutics, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Protalix BioTherapeutics's EPS forecast?
Analysts forecast $0.24 per share for 2026 (range $0.19 to $0.29); for 2027 the estimate is $0.05.
What is Protalix BioTherapeutics's revenue forecast?
The average revenue estimate for 2026 is $82.2 million, growth of 55.8%; for 2027 it is $66.5 million.
When does Protalix BioTherapeutics report earnings?
Protalix BioTherapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.02.
Does Protalix BioTherapeutics usually beat earnings estimates?
Protalix BioTherapeutics reported EPS at or above the analyst estimate in 4 of the last 12 quarters.